neuroendocrine tumours
Conditions
Brief summary
The difference in PFS between patients continuing or stopping SSA after initiating PRRT, as assessed by blinded local radiologists on cross-sectional imaging; progression is defined through RECIST 1.1 standardized framework., The difference in PFS between patients continuing or stopping SSA after initiating targeted therapy, as assessed by blinded local radiologists on cross-sectional imaging; progression is defined through RECIST 1.1 standardized framework., The difference in TTD in patients continuing or stopping second-line therapy with SSAs after initiating PRRT., The difference in TTD in patients continuing or stopping second-line therapy with SSAs after initiating targeted therapy.
Detailed description
PFS rate according to RECIST 1.1 at 18 months per substudy, The difference in pooled PFS and TTD of both substudies, Overall survival per substudy and pooled over both substudies, Response rates per substudy and pooled over both substudies, Quality of life (QoL), Cost-effectiveness, Toxicity
Interventions
Sponsors
Antwerp University Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in PFS between patients continuing or stopping SSA after initiating PRRT, as assessed by blinded local radiologists on cross-sectional imaging; progression is defined through RECIST 1.1 standardized framework., The difference in PFS between patients continuing or stopping SSA after initiating targeted therapy, as assessed by blinded local radiologists on cross-sectional imaging; progression is defined through RECIST 1.1 standardized framework., The difference in TTD in patients continuing or stopping second-line therapy with SSAs after initiating PRRT., The difference in TTD in patients continuing or stopping second-line therapy with SSAs after initiating targeted therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS rate according to RECIST 1.1 at 18 months per substudy, The difference in pooled PFS and TTD of both substudies, Overall survival per substudy and pooled over both substudies, Response rates per substudy and pooled over both substudies, Quality of life (QoL), Cost-effectiveness, Toxicity | — |
Countries
Belgium, Netherlands
Outcome results
None listed